-
Osowicki, J, Azzopardi, KI, McIntyre, L, Rivera-Hernandez, T, Ong, C-LY, Baker, C, Gillen, CM, Walker, MJ, Smeesters, PR, Davies, MR, et al.
A Controlled Human Infection Model of Group A Streptococcus Pharyngitis: Which Strain and Why?.
mSphere
4(1)
:
2019
view publication
-
Hodson, C, Yang, J, Hocking, DM, Azzopardi, K, Chen, Q, Holien, JK, Parker, MW, Tauschek, M, Robins-Browne, RM.
Control of Virulence Gene Expression by the Master Regulator, CfaD, in the Prototypical Enterotoxigenic Escherichia coli Strain, H10407..
Front Microbiol
8:
1525
2017
view publication
-
Ingle, DJ, Tauschek, M, Edwards, DJ, Hocking, DM, Pickard, DJ, Azzopardi, KI, Amarasena, T, Bennett-Wood, V, Pearson, JS, Tamboura, B, et al.
Evolution of atypical enteropathogenic E. coli by repeated acquisition of LEE pathogenicity island variants..
Nat Microbiol
1:
15010
2016
view publication
-
Zeng, W, Azzopardi, K, Hocking, D, Wong, CY, Robevska, G, Tauschek, M, Robins-Browne, RM, Jackson, DC.
A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli..
Vaccine
30(32)
:
4800 -4806
2012
view publication
-
Baldi, DL, Higginson, EE, Hocking, DM, Praszkier, J, Cavaliere, R, James, CE, Bennett-Wood, V, Azzopardi, KI, Turnbull, L, Lithgow, T, et al.
The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli..
Infect Immun
80(6)
:
2042 -2052
2012
view publication